Alps Advisors Inc. raised its stake in shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 23.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,026 shares of the company’s stock after buying an additional 5,143 shares during the period. Alps Advisors Inc. owned 0.11% of Syndax Pharmaceuticals worth $237,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SNDX. Parametric Portfolio Associates LLC increased its stake in shares of Syndax Pharmaceuticals by 61.4% in the second quarter. Parametric Portfolio Associates LLC now owns 36,565 shares of the company’s stock worth $511,000 after purchasing an additional 13,911 shares during the period. OxFORD Asset Management LLP increased its stake in shares of Syndax Pharmaceuticals by 75.0% in the third quarter. OxFORD Asset Management LLP now owns 48,442 shares of the company’s stock worth $574,000 after purchasing an additional 20,753 shares during the period. Vanguard Group Inc. increased its stake in shares of Syndax Pharmaceuticals by 25.1% in the second quarter. Vanguard Group Inc. now owns 512,624 shares of the company’s stock worth $7,161,000 after purchasing an additional 102,700 shares during the period. Northern Trust Corp increased its stake in shares of Syndax Pharmaceuticals by 94.7% in the second quarter. Northern Trust Corp now owns 130,196 shares of the company’s stock worth $1,819,000 after purchasing an additional 63,336 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Syndax Pharmaceuticals by 115.9% in the second quarter. TIAA CREF Investment Management LLC now owns 49,484 shares of the company’s stock worth $691,000 after purchasing an additional 26,560 shares during the period. Institutional investors own 59.91% of the company’s stock.

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) opened at $9.48 on Thursday. Syndax Pharmaceuticals Inc has a 12 month low of $7.41 and a 12 month high of $15.70. The stock has a market capitalization of $231.22 and a PE ratio of -3.35.

A number of equities analysts have recently commented on the company. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. BidaskClub upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Finally, B. Riley assumed coverage on Syndax Pharmaceuticals in a research note on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $24.38.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://theolympiareport.com/2018/02/15/alps-advisors-inc-buys-5143-shares-of-syndax-pharmaceuticals-inc-sndx.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.